Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Elliott

Showing results (141-150 of 157) with videos related to

Pageof 16
Sort By:
Cancer Research|June 18, 2025
XPO1 R749Q Mutations Co-occur with POLE Mutations in Cancer and Can Be Targeted to Overcome ChemoresistanceTulasigeri M Totiger, Wannasiri Chiraphapphaiboon, Yasmine Baca, et al.
Science Advances|January 31, 2024
Targeting prostate tumor low-molecular weight tyrosine phosphatase for oxidation-sensitizing therapyStephanie M Stanford, Tiffany P Nguyen, Joseph Chang, et al.
Infectious Agents and Cancer|May 2, 2026
Genomic and transcriptomic differences between neuroendocrine neoplasms and carcinomas with human papillomavirus (HPV)Morgann Madill, Udhayvir Grewal, Harris Krause, et al.
Research in Social & Administrative Pharmacy : RSAP|December 21, 2025
Methods used to identify and classify medication-related admissions and readmissions to hospitals: A systematic reviewLinda Krogh, Stephen Carter, Shania Liu, et al.
Prostate Cancer and Prostatic Diseases|February 28, 2024
Natural Killer Cell Infiltration in Prostate Cancers Predict Improved Patient OutcomesNicholas A Zorko, Allison Makovec, Andrew Elliott, et al.
JAMA Oncology|May 29, 2025
Expression of Membrane Targets for Therapeutics in RET-Positive Non-Small Cell Lung CancerArianna Marinello, Maria Rosa Ghigna, Julia K Rotow, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 2023
Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical OutcomesJustin Hwang, Xiaolei Shi, Andrew Elliott, et al.
European Urology|May 13, 2026
IDH1 Mutations Are Associated with Favorable Outcomes in Prostate CancerLuka Cavka, Subhiksha Nandakumar, Qingqing Wu, et al.
Oncogene|November 3, 2021
Molecular characteristics and clinical outcomes of patients with Neurofibromin 1-altered metastatic colorectal cancerHiroyuki Arai, Andrew Elliott, Joshua Millstein, et al.
Cell Reports. Medicine|June 26, 2026
Case of complete response to immunotherapy in MMR-deficient prostate cancer associated with NK-like and CD4<sup>+</sup>CD8<sup>+</sup> T cellsAlexander K Tsai, John R Lozada, Philippa R Kennedy, et al.
Pageof 16

Showing results (141-150 of 157) with videos related to

Sort By:
Pageof 16
Cancer Research|June 18, 2025
XPO1 R749Q Mutations Co-occur with POLE Mutations in Cancer and Can Be Targeted to Overcome ChemoresistanceTulasigeri M Totiger, Wannasiri Chiraphapphaiboon, Yasmine Baca, et al.
Science Advances|January 31, 2024
Targeting prostate tumor low-molecular weight tyrosine phosphatase for oxidation-sensitizing therapyStephanie M Stanford, Tiffany P Nguyen, Joseph Chang, et al.
Infectious Agents and Cancer|May 2, 2026
Genomic and transcriptomic differences between neuroendocrine neoplasms and carcinomas with human papillomavirus (HPV)Morgann Madill, Udhayvir Grewal, Harris Krause, et al.
Research in Social & Administrative Pharmacy : RSAP|December 21, 2025
Methods used to identify and classify medication-related admissions and readmissions to hospitals: A systematic reviewLinda Krogh, Stephen Carter, Shania Liu, et al.
Prostate Cancer and Prostatic Diseases|February 28, 2024
Natural Killer Cell Infiltration in Prostate Cancers Predict Improved Patient OutcomesNicholas A Zorko, Allison Makovec, Andrew Elliott, et al.
JAMA Oncology|May 29, 2025
Expression of Membrane Targets for Therapeutics in RET-Positive Non-Small Cell Lung CancerArianna Marinello, Maria Rosa Ghigna, Julia K Rotow, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 2023
Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical OutcomesJustin Hwang, Xiaolei Shi, Andrew Elliott, et al.
European Urology|May 13, 2026
IDH1 Mutations Are Associated with Favorable Outcomes in Prostate CancerLuka Cavka, Subhiksha Nandakumar, Qingqing Wu, et al.
Oncogene|November 3, 2021
Molecular characteristics and clinical outcomes of patients with Neurofibromin 1-altered metastatic colorectal cancerHiroyuki Arai, Andrew Elliott, Joshua Millstein, et al.
Cell Reports. Medicine|June 26, 2026
Case of complete response to immunotherapy in MMR-deficient prostate cancer associated with NK-like and CD4<sup>+</sup>CD8<sup>+</sup> T cellsAlexander K Tsai, John R Lozada, Philippa R Kennedy, et al.
Pageof 16